The Executive Exchange Series (EES)
Building interconnectivity builds an industry
Recent EES Events
On September 18th, OBIO lead a workshop with two financial experts who can help keep this from happening to you.
John Jordan (CFO, RNA Diagnostics) and Jim Cooke (CFO, Stoneybridge Partners) will be leading the workshop, addressing topics such as:
How to build in headroom for slippage and unexpected costs
What level of budget should you present to your board and to investors
Facing the reality of comparing actual to budget
Join OBIO on Tuesday, June 26th to identify non-dilutive funding programs, learn to prepare your applications, and what you should be aware of after being awarded. Sign up for one or all of four sessions designed to help you build your early-stage strategy toolbox.
On June 25th, join OBIO for a unique opportunity to hear from experienced investors and analysts about how VCs think about valuation and how valuation is translated into deal structure.
Find out more about:
ROI needed for investors
Valuation methods commonly used
Criteria for selecting comparable companies
Characteristics of equity and debenture instruments
Consequences of dilution and follow-on investment
Calculating exit payouts
Red flags and how to prepare to discuss valuation with investors
Get behind-the-scenes on the recent changes at the FDA and learn more about how regulatory process changes affect your company:
Understand FDA’s vision and approach to driving innovation under Commissioner Dr. Scott Gottlieb, and how recent changes in the agency will affect premarket submissions and inspections.
Learn how and when you should be engaging with the FDA.
Find out what the FDA is looking for in 510(k), DeNovo, and PMA submissions & recent approvals of devices with AI and machine learning features.
Join OBIO on Tuesday, June 12th to hear from industry experts on the importance of strategic marketing for health science companies, featuring our keynote speaker, Dr. Brian Jahns, the Senior VP, Commercial and Business Development at Trillium Therapeutics Inc. where he is responsible for providing commercial input clinical and regulatory strategy, as well as carrying out business development activities. Dr. Jahns will discuss why it’s critical for early stage health science companies to develop a strategic plan, the impact of those plans on successful commercialization and lessons learned from his experience in the health science industry.
If you are heading to RESI or BIO in Boston, please join Gail Garland, OBIO CEO, for dinner and an opportunity to network and exchange notes with fellow OBIO companies. Adam Buckley, VP of Business Development, VBI Vaccines and OBIO Board Director, will speak about the VBI Vaccines story.
Participants got a chance to learn from market research professionals on how to effectively target market and set strategic goals using research reports, market segmentation, and competitive analysis.
On May 3, OBIO welcomed health science leaders, CEOs and the investment community to the tenth annual OBIO Leadership Event. Hosted at SPiN, the event also saw the launch of Use It or Lose It: Industry Solutions to Ontario's Commercialization Gap, OBIO's 2018 Industry Report. Check out the event photo gallery and recap.
Get an in-depth view of the attractive non-dilutive funding programs offered by CQDM which have supported several Ontario health science companies.
✓ Quantum Leap & SynergicQc Programs
✓ Application & Funding Process
✓ Mentorship & Large Pharma Partners